SlideShare a Scribd company logo
1 of 10
Download to read offline
Binder Design
                             Client: TAP Pharmaceuticals
                             Design, production & project
                             management




Connie Miley Cook • Healthcare Portfolio • 847.863.6050
Sell Sheet
                             Client: Baxter Healthcare Corporation,
                             Medication Delivery Division
                             Design & production




Connie Miley Cook • Healthcare Portfolio • 847.863.6050
-19, 2011
September 17
              chusetts
Boston, Massa




                                                  Invitation, Cardiac Device Conference
                                                  Client: Beth Israel Hospital
                                                  Design, production & project management




                         Connie Miley Cook • Healthcare Portfolio • 847.863.6050
Solutions Brochure, Pharmaceutical Market
                         Client: Domino
                         Design, production & project management




Connie Miley Cook • Healthcare Portfolio • 847.863.6050
sment for Coronar y Heart Disease
              -Year Risk Asses
                                                                                                                                                                          disease
                                                                                                                                                       nary artery

Framingham 10
                                                                                                                              tory of coro
                                                                                                        clu     de family his
                                                                                     Does not in
                                                                                                                          Points                           Age                              Interactive
      BLUE=MEN                                                                                                             Age
                                                                                                                                           Age            70-79 y
      PURPLE=W OM
                  EN                                                                                          Age                         60-69 y                                           Cardiovascular
                                                                 Total                     Age                            50-59 y
                                                                                                             40-49 y
                                                               Choles terol,              20-39 y                                                                                           Risk Assessment
                              Points                             mg/dL
       Age, y                                                                                                                                                            Points
                                                                   <160                                                                                                                     Client: Nebraska
       20-34
                                                                  160-199                                                                                                  0                Heart Institute
       35-39
                                                                  200-239                                                                                                                   Design &
        40-44
                                                                   240-279                                                                                                                  production
        45-49
                                                                      280                                                      Points                         Age         Points
         50-54                                                                                                                                Age            70-79 y
                                                                                                                                Age          60-69 y
                                                                                                                Age
         55-59                                                                                Age              40-49 y
                                                                                                                               50-59 y                                       0
          60-64                                 Points                                       20-39 y
          65-69
                                                   0             Nonsmoker
           70-74
                                                                 Smoker                                                                               10-Year Risk,
                                                                                                                                                                    %
           75-79                                                                                                                     Point Total
                                                                                                                           %
                                                                                                             10-Year Risk,
                                                                                          Point Total                                     <9
                                   Points                                                                                                   9
           HDL, mg/dL                                                                          <0
             60                                     Points                                       0                                         10
                                                                                                 1                                          11
           50-59
            40-49
                                                       0                                          2                                         12
                                                                                                  3                                          13
             <40
                                                                                                   4                                         14
                                                            If Treated
                                 Hg       If Untreated                                             5                                          15
                            mm
              Systolic BP,                                                                          6                                         16
              <120
                                                                                                                                                                               TOTAL
                                                                               Poin ts              7                                          17                               POINTS
               120-129                                                                               8                                         18
               130-139                                                            0                  9                                          19                                  0
                140-159                                                                             10                                          20
                  60                                                                                 11                                          21
                                                                                                                                                                                   TOTAL
                                                                    nel III Report.                  12                                          22
                                                  ult Treatment Pa                                                                                                  2               RIS K
                                     y of NCEP Ad                    ris k factors.                                                               23
              Adapted   from summar                    art Diseas e)                                  13
                                          (Coronary He                                                                                                              7
                             with 2+ CHD                                                                                                          24
               *For pers ons                                             BE USED
                                                                                                      14
                                                                                                                                                                     0
                                                       T IS ONLY TO                     .
                              ATION   ON THIS SHEE            NS FROM       YOUR DOCTOR                15                                          25
                THE INFORM                     INSTRUCTIO
                                ITH SPECIFIC                                                           16
                TOGETHER W                                                                              17




                                                                                       Connie Miley Cook • Healthcare Portfolio • 847.863.6050
Patient Education, Oncology &
Neuroscience Therapeutic Areas
Client: AstraZeneca Pharmaceuticals
Design, production & project
management




                                      Connie Miley Cook • Healthcare Portfolio • 847.863.6050
Capabilities Brochure
                         Client: HealthRealty Partners
                         Design, production & project management




Connie Miley Cook • Healthcare Portfolio • 847.863.6050
Promotional Newsletter, Medical Devices
                         Client: D-Med
                         Design, production & project management




Connie Miley Cook • Healthcare Portfolio • 847.863.6050
Patient Education
                         Client: Cardiovascular Associates: The
                         Heart Care of Central and Northern
                         Wisconsin
                         Design, production & project management




Connie Miley Cook • Healthcare Portfolio • 847.863.6050
Product Sell Sheet
                         Client: Niche Pharmaceuticals
                         Design, production & project management




Connie Miley Cook • Healthcare Portfolio • 847.863.6050

More Related Content

Viewers also liked

CCEDIN Invasive Species Early Detection 8.19.09
CCEDIN Invasive Species Early Detection 8.19.09CCEDIN Invasive Species Early Detection 8.19.09
CCEDIN Invasive Species Early Detection 8.19.09Robert Emanuel
 
Student Led Conferences 2009
Student Led Conferences 2009Student Led Conferences 2009
Student Led Conferences 2009Sacha Cotter
 
Intro To Lid Hdgi 2 10 10
Intro To Lid Hdgi 2 10 10Intro To Lid Hdgi 2 10 10
Intro To Lid Hdgi 2 10 10Robert Emanuel
 
移动产品成功秘诀
移动产品成功秘诀移动产品成功秘诀
移动产品成功秘诀Wang Jian
 
C2 Portfolio 2010
C2 Portfolio 2010C2 Portfolio 2010
C2 Portfolio 2010Connie Cook
 
Invasive spp. Early Detection for Longview Timber 4.29.10
Invasive spp. Early Detection for Longview Timber 4.29.10Invasive spp. Early Detection for Longview Timber 4.29.10
Invasive spp. Early Detection for Longview Timber 4.29.10Robert Emanuel
 
服务海量用户
服务海量用户服务海量用户
服务海量用户Wang Jian
 
为完美的老板工作
为完美的老板工作为完美的老板工作
为完美的老板工作Wang Jian
 
Why low impact development pccpac
Why low impact development pccpacWhy low impact development pccpac
Why low impact development pccpacRobert Emanuel
 
High Desert Green Industry Invasive Spp
High Desert Green Industry  Invasive  SppHigh Desert Green Industry  Invasive  Spp
High Desert Green Industry Invasive SppRobert Emanuel
 
Gardening for Better Watersheds in Oregon
Gardening for Better Watersheds in OregonGardening for Better Watersheds in Oregon
Gardening for Better Watersheds in OregonRobert Emanuel
 
战略与执行
战略与执行战略与执行
战略与执行Wang Jian
 

Viewers also liked (14)

CCEDIN Invasive Species Early Detection 8.19.09
CCEDIN Invasive Species Early Detection 8.19.09CCEDIN Invasive Species Early Detection 8.19.09
CCEDIN Invasive Species Early Detection 8.19.09
 
Intro To Lid 9.17.09
Intro To Lid 9.17.09Intro To Lid 9.17.09
Intro To Lid 9.17.09
 
Student Led Conferences 2009
Student Led Conferences 2009Student Led Conferences 2009
Student Led Conferences 2009
 
Intro To Lid Hdgi 2 10 10
Intro To Lid Hdgi 2 10 10Intro To Lid Hdgi 2 10 10
Intro To Lid Hdgi 2 10 10
 
移动产品成功秘诀
移动产品成功秘诀移动产品成功秘诀
移动产品成功秘诀
 
C2 Portfolio 2010
C2 Portfolio 2010C2 Portfolio 2010
C2 Portfolio 2010
 
Invasive spp. Early Detection for Longview Timber 4.29.10
Invasive spp. Early Detection for Longview Timber 4.29.10Invasive spp. Early Detection for Longview Timber 4.29.10
Invasive spp. Early Detection for Longview Timber 4.29.10
 
服务海量用户
服务海量用户服务海量用户
服务海量用户
 
为完美的老板工作
为完美的老板工作为完美的老板工作
为完美的老板工作
 
Why low impact development pccpac
Why low impact development pccpacWhy low impact development pccpac
Why low impact development pccpac
 
High Desert Green Industry Invasive Spp
High Desert Green Industry  Invasive  SppHigh Desert Green Industry  Invasive  Spp
High Desert Green Industry Invasive Spp
 
Gardening for Better Watersheds in Oregon
Gardening for Better Watersheds in OregonGardening for Better Watersheds in Oregon
Gardening for Better Watersheds in Oregon
 
战略与执行
战略与执行战略与执行
战略与执行
 
拉动
拉动拉动
拉动
 

Cmc Hc Portfolio 2011

  • 1. Binder Design Client: TAP Pharmaceuticals Design, production & project management Connie Miley Cook • Healthcare Portfolio • 847.863.6050
  • 2. Sell Sheet Client: Baxter Healthcare Corporation, Medication Delivery Division Design & production Connie Miley Cook • Healthcare Portfolio • 847.863.6050
  • 3. -19, 2011 September 17 chusetts Boston, Massa Invitation, Cardiac Device Conference Client: Beth Israel Hospital Design, production & project management Connie Miley Cook • Healthcare Portfolio • 847.863.6050
  • 4. Solutions Brochure, Pharmaceutical Market Client: Domino Design, production & project management Connie Miley Cook • Healthcare Portfolio • 847.863.6050
  • 5. sment for Coronar y Heart Disease -Year Risk Asses disease nary artery Framingham 10 tory of coro clu de family his Does not in Points Age Interactive BLUE=MEN Age Age 70-79 y PURPLE=W OM EN Age 60-69 y Cardiovascular Total Age 50-59 y 40-49 y Choles terol, 20-39 y Risk Assessment Points mg/dL Age, y Points <160 Client: Nebraska 20-34 160-199 0 Heart Institute 35-39 200-239 Design & 40-44 240-279 production 45-49 280 Points Age Points 50-54 Age 70-79 y Age 60-69 y Age 55-59 Age 40-49 y 50-59 y 0 60-64 Points 20-39 y 65-69 0 Nonsmoker 70-74 Smoker 10-Year Risk, % 75-79 Point Total % 10-Year Risk, Point Total <9 Points 9 HDL, mg/dL <0 60 Points 0 10 1 11 50-59 40-49 0 2 12 3 13 <40 4 14 If Treated Hg If Untreated 5 15 mm Systolic BP, 6 16 <120 TOTAL Poin ts 7 17 POINTS 120-129 8 18 130-139 0 9 19 0 140-159 10 20 60 11 21 TOTAL nel III Report. 12 22 ult Treatment Pa 2 RIS K y of NCEP Ad ris k factors. 23 Adapted from summar art Diseas e) 13 (Coronary He 7 with 2+ CHD 24 *For pers ons BE USED 14 0 T IS ONLY TO . ATION ON THIS SHEE NS FROM YOUR DOCTOR 15 25 THE INFORM INSTRUCTIO ITH SPECIFIC 16 TOGETHER W 17 Connie Miley Cook • Healthcare Portfolio • 847.863.6050
  • 6. Patient Education, Oncology & Neuroscience Therapeutic Areas Client: AstraZeneca Pharmaceuticals Design, production & project management Connie Miley Cook • Healthcare Portfolio • 847.863.6050
  • 7. Capabilities Brochure Client: HealthRealty Partners Design, production & project management Connie Miley Cook • Healthcare Portfolio • 847.863.6050
  • 8. Promotional Newsletter, Medical Devices Client: D-Med Design, production & project management Connie Miley Cook • Healthcare Portfolio • 847.863.6050
  • 9. Patient Education Client: Cardiovascular Associates: The Heart Care of Central and Northern Wisconsin Design, production & project management Connie Miley Cook • Healthcare Portfolio • 847.863.6050
  • 10. Product Sell Sheet Client: Niche Pharmaceuticals Design, production & project management Connie Miley Cook • Healthcare Portfolio • 847.863.6050